48-week data from the study of adalimumab in children with juvenile rheumatoid arthritis (JRA) | Charles Explorer

48-week data from the study of adalimumab in children with juvenile rheumatoid arthritis (JRA)

Publikace

Abstrakt

48-week data from the study of adalimumab in children with juvenile rheumatoid arthritis (JRA)

Osoby